Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
Aroor, Annayya R., Das, Nitin A., Carpenter, Andrea J., Habibi, Javad, Jia, Guanghong, Ramirez-Perez, Francisco I., Martinez-Lemus, Luis, Manrique-Acevedo, Camila M., Hayden, Melvin R., Duta, Cornel,Том:
17
Мова:
english
Журнал:
Cardiovascular Diabetology
DOI:
10.1186/s12933-018-0750-8
Date:
December, 2018
Файл:
PDF, 4.99 MB
english, 2018